A novel complex formed by ruthenium (111) and the sequestering ligand 1,2-propylenediaminetetraacetic acid (PDTA) has been synthetized and characterized. The structure of the monomeric compound, studied by X-ray diffraction, shows an almost symmetric octahedral geometry around the metal ion, with two chlorine atoms in a cis conformation. The antitumour activity against a variety of murine and human cancers is reported.
Introduction
Many compounds of transition metals with 1,2-propylenediamine-N,N,N',N'-tetraacetic acid (PDTA, Figure 1 ), have been studied in recent years, although those formed by ruthenium have been object of scarce attention(I-4). Compounds formed by this chelating agent, a methyl derivative of EDTA, are of about two orders of magnitude more stable than the analogs formed with the parent ligand. Furthermore, ruthenium complexes with PDTA may be of interest because of the easy conversion of this element from one oxidation state into another at the appropriate experimental conditions, and because of the tendency of its compounds to undergo hydrolysis.
Advantage can be taken from the ready availability of both the Ru(lll) and Ru(ll) oxidation states under physiological conditions and the general inertness of these ions toward substitution, when coordinated to nitrogen ligands (5) . All the referred properties are in close connection to the ability of the ruthenium complexes to act as potential antitumour drugs (6) (7) (8) (9) . Ruthenium complexes with polydentate chelating agents ("secondary ligands") may be considered as prodrugs against different tumors. The role of the secondary ligand is to stabilize the ruthenium (111) cation so that the metal is not delivered to the tissues during its transportation in the body and the whole complex remains unchanged. In this way, a drastic lowering of the host toxicity produced by these potential drugs have been observed. Once the complex reaches the hypoxic areas proper of tumor tissues, the metal ion is reduced "in situ", this feature promoting the accumulation of ruthenium in tumor masses (10, 11 (2) 17342 (6) 149 (17) -7310 (8) 43.4(3) C (1) 596 (2) 1449 (5) 1976 (3) 29(1) C (2) -167 (2) 1446 (5) 1634 (3) 28(1) C (3) -665 (2) 2279 (7) 2352 (3) 41 (1) N (1) 1097 (2) 555 (4) 1311 (2) 26(1) C (11 1840(2) 1285 (6) 1427 (3) 34 (1 C(12) 1901 (2) 3070 (6) 932 (3) 31 (1) O (11) 1415 (2) 3472 (4) 366 (2) 33 (1) O (12) 2427 (2) 4049 (5) 1103 (2) 44(1 C (13) 1068 (2) -1417 (5) 1375 (3) 30 (1) C (14) 1310 (2) -2223 (6) 2271 (3) 33 (1) O (13) 1591 (2) -1413 (4) 2898 (2) 47 (1) O (14) 1179 (2) -3953 (4) 2293 (2) 43(1 N(2) -193 (2) 2339 (4) 698 (2) 25 (1) Figure   2 . Crystal and refinement data for [RuLCI2]H.4H20 are summarized in Table 2 . Bond distances and angles are indicated in Table 3 All water molecules and the carboxylic acid groups act as donors in hydrogen bonding (see Table 3 ), the acceptors being water molecules, carboxylate groups and chlorine atoms. A view of some of these hydrogen bonds is displayed in Figure 3 . The oxidation state of ruthenium is +3, as shown by magnetic measurements, so an extra proton must be attached to any of the water molecules in order to balance the charge of the complex anion. Nevertheless, difference maps and the hydrogen bonds displayed in Table 3 let us to identify clearly only two hydrogen atoms per water oxygen, the remaining proton being probably disordered among water molecules.
Antitumor activity
The antitumor activity of the synthesized ruthenium complex has been evaluated against the murine and human tumors mentioned in the experimental part of this paper. The results obtained are reported in Table 5 . The complex exhibits a noteworthy activity against Ehrlich ascitic tumor, with a maximum T/C value of 460 correspopnding to a dose of 120 mg/Kg. The ruthenium drug presents an important antitumor action against the murine leukemias L1210 and P388, it being the optimum dose the same as in EAT case. The most important finding is the marked cytotoxic effect shown by the ruthenium complex against the MX-1 human mammary tumor, even larger than in the case of DCTARu compound (9) . Cures are complete in the EAT case with a long term survivors of 8/8 and appreciable in the L1210 and P388 leukemias (LTS of 4/8 and 3/8, respectively). The complex is exceptionally well tolerated and shows an absolute lack of nephrotoxicity and liver toxicity at all given doses. Moreover, myelosuppression is not observed. Figure 4c , in which the second inflection has disappeared. Consequently, the coordinated PDTA contains two free carboxylic groups even after the replacement of the chlorine atom.
Infrared spectroscopy
The isolated complex shows bands in the infrared spectra indicating the presence of both, non-coordinated -COOH groups (1720 cm-1) and coordinated -CO0" groups (1610 cm-1). Additional important vibrational modes are registered at 530 cm-1 (Ru-N bond) and by a split peak at 330 cm 1 and 290 cm1, this fact indicating the presence of two chlorine atoms bonded to ruthenium in cis positions. Other characteristic peaks of the complex appear in Table 4 . 
